Anthera Pharmaceuticals is a development stage biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation. As of Dec 31 2011, Co.'s product candidates included: blisibimod, which is a peptibody antagonist of the B-cell activating factor cytokine, in Phase 2 clinical trials that is initially being developed as a treatment for lupus; and varespladib and varespladib sodium, which are designed to inhibit a novel enzyme target known as secretory phospholipase A2. In addition, blisibimod has been associated with other diseases, including, lupus nephritis, rheumatoid arthritis, multiple sclerosis, and Sjogren's Syndrome.
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20
minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.
